Fully recruited EPIC-Skin international study for the treatment of Non-Melanoma Skin Cancer

/PRNewswire/ -- OncoBeta® GmbH, a medical device company specialised in innovative epidermal radioisotope therapies, has confirmed the phase IV international...

Related Keywords

Garching ,Bayern ,Germany ,Vienna ,Wien ,Austria ,London ,City Of ,United Kingdom ,Pretoria ,Gauteng ,South Africa ,Ghana ,New York ,United States ,Perth ,Western Australia ,Australia ,Munich ,Sydney ,New South Wales ,Gold Coast ,Australian ,Mike Sathekge ,Prnewswire Oncobeta ,Oncobeta Gmb ,Gerhard Dahlhoff ,Shannond Brown ,Internationalj Nucl ,Australian Therapeutic Goods Administration ,Linkedin ,Facebook ,Therapeutic Nuclear Medicine ,Instagram ,Complete Response Rate ,Personalised Irradiation ,Patient Reported Outcome Measures ,Nuclear Medicine ,Steve Biko Academic Hospital ,Medical Director ,Managing Director ,Skin Cancer Therapy ,Basal Cell Carcinomas ,Squamous Cell Carcinomas ,Disease Cancer Collaboration ,Risk Factors ,Oncobeta Gmbh ,